JP2007501857A - 四環系ベンズアミド誘導体およびその使用方法 - Google Patents

四環系ベンズアミド誘導体およびその使用方法 Download PDF

Info

Publication number
JP2007501857A
JP2007501857A JP2006532301A JP2006532301A JP2007501857A JP 2007501857 A JP2007501857 A JP 2007501857A JP 2006532301 A JP2006532301 A JP 2006532301A JP 2006532301 A JP2006532301 A JP 2006532301A JP 2007501857 A JP2007501857 A JP 2007501857A
Authority
JP
Japan
Prior art keywords
alkyl
compound
substituted
pharmaceutically acceptable
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006532301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007501857A5 (https=
Inventor
ジャグタップ，プラカッシュ
ウィリアムズ，ウィリアム
ニヴォロツキン，アレクサンダー
スザボ，クサバ
Original Assignee
イノテック ファーマシューティカルズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノテック ファーマシューティカルズ コーポレーション filed Critical イノテック ファーマシューティカルズ コーポレーション
Publication of JP2007501857A publication Critical patent/JP2007501857A/ja
Publication of JP2007501857A5 publication Critical patent/JP2007501857A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2006532301A 2003-02-28 2004-02-26 四環系ベンズアミド誘導体およびその使用方法 Pending JP2007501857A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45092503P 2003-02-28 2003-02-28
PCT/US2004/005737 WO2005009398A2 (en) 2003-02-28 2004-02-26 Tetracyclic benzamide derivatives and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2007501857A true JP2007501857A (ja) 2007-02-01
JP2007501857A5 JP2007501857A5 (https=) 2007-04-05

Family

ID=34102592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006532301A Pending JP2007501857A (ja) 2003-02-28 2004-02-26 四環系ベンズアミド誘導体およびその使用方法

Country Status (11)

Country Link
US (2) US7217709B2 (https=)
EP (1) EP1603567A4 (https=)
JP (1) JP2007501857A (https=)
KR (1) KR20050118169A (https=)
CN (1) CN100398519C (https=)
AU (1) AU2004258801A1 (https=)
BR (1) BRPI0407757A (https=)
CA (1) CA2517260A1 (https=)
PL (1) PL378331A1 (https=)
RU (1) RU2005130169A (https=)
WO (1) WO2005009398A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520817A (ja) * 2003-02-28 2006-09-14 イノテック ファーマシューティカルズ コーポレイション イソキノリン誘導体およびその使用方法

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
JP2007501857A (ja) * 2003-02-28 2007-02-01 イノテック ファーマシューティカルズ コーポレーション 四環系ベンズアミド誘導体およびその使用方法
EA200601558A1 (ru) * 2004-02-26 2007-08-31 Инотек Фармасьютикалз Корпорейшн Производные изохинолинов и способы их использования
US20050261288A1 (en) * 2004-02-26 2005-11-24 Prakash Jagtap Tetracyclic lactam derivatives and uses thereof
CA2571001A1 (en) * 2004-06-16 2006-01-26 Inotek Pharmaceuticals Corporation Methods for treating or preventing erectile dysfunction or urinary incontinence
WO2006093677A1 (en) * 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Tetracyclic sulfonamide compounds and methods of use thereof
RU2007135362A (ru) * 2005-02-25 2009-03-27 Инотек Фармасьютикалз Корпорейшн (Us) Тетрациклические амино- и карбоксамидосоединения и способ их применения
JP2008531561A (ja) * 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション イソキノリン化合物およびその使用方法
CA2617101A1 (en) * 2005-08-08 2007-02-15 Boehringer Ingelheim International Gmbh Method for the protection against the risk of cardiac disorders comprising administration of tiotropium salts
CN101316592A (zh) * 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
CA2629530C (en) 2005-11-14 2014-07-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services N-substituted indenoisoquinolines and syntheses thereof
US9399660B2 (en) 2005-11-14 2016-07-26 Purdue Research Foundation N-substituted indenoisoquinolines and syntheses thereof
WO2007117289A2 (en) * 2005-12-14 2007-10-18 Inotek Pharmaceuticals Corporation Methods for treating or preventing erectile dysfunction or urinary incontinence
MX2009009183A (es) * 2007-02-28 2009-09-07 Inotek Pharmaceuticals Corp Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos.
WO2008114114A2 (en) * 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
JP2009196973A (ja) * 2007-09-26 2009-09-03 Santen Pharmaceut Co Ltd キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤
JP2009096804A (ja) * 2007-09-26 2009-05-07 Santen Pharmaceut Co Ltd キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤
US20100137976A1 (en) * 2008-12-02 2010-06-03 Medtronic Vascular, Inc. Systems and Methods for Treating Heart Tissue Via Localized Delivery of Parp Inhibitors
WO2010077663A2 (en) * 2008-12-08 2010-07-08 Inotek Pharmaceuticals Corporation Substituted tetracyclic 1h-indeno (1,2-b) pyridine-2 (5h)-one analogs thereof and uses thereof
ITFI20090005A1 (it) * 2009-01-19 2010-07-20 Alberto Chiarugi Formulazioni farmaceutiche per indurre immunosoppressione attraverso l'inibizione del fenomeno dell'epitope spreading e loro uso.
EP3613729A1 (en) * 2009-06-10 2020-02-26 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds
KR101034051B1 (ko) * 2009-07-13 2011-05-11 (재)광주테크노파크 신규한 이소인돌로[2,1-ｂ]이소퀴놀린온 유도체 및 이를 함유하는 항암제 조성물
EP2280011A1 (en) * 2009-07-28 2011-02-02 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Condensed pyridine derivatives useful as potent inhibitors of the protein kinase CK2
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2011094416A1 (en) 2010-01-27 2011-08-04 Purdue Research Foundation Substituted norindenoisoquinolines, syntheses thereof, and methods of use
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
CN102250000A (zh) * 2010-05-17 2011-11-23 中国人民解放军第二军医大学 茚并喹啉酮类化合物及其制备方法和用途
EP2578587B1 (en) * 2010-05-24 2016-09-07 Hande Starlake Bioscience Co., Ltd. Pyrazole derivatives
US9073920B2 (en) 2010-08-17 2015-07-07 Purdue Research Foundation Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes therfor
CA2808210C (en) 2010-08-20 2019-10-01 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds having alk inhibitory activity and compositions thereof
TW201307347A (zh) 2010-11-01 2013-02-16 Arqule Inc 經取代苯並－咪唑並－吡啶並－二氮呯化合物
US9682990B2 (en) 2011-05-25 2017-06-20 Purdue Research Foundation Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors
US9328073B2 (en) 2011-05-25 2016-05-03 Purdue Research Foundation Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors
US8912213B2 (en) 2012-04-13 2014-12-16 Purdue Research Foundation Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (TDP1)- topoisomerase I (TOP1) inhibitors
US8686146B2 (en) 2012-07-13 2014-04-01 Purdue Research Foundation Azaindenoisoquinoline topoisomerase I inhibitors
US9034870B2 (en) 2012-07-13 2015-05-19 Purdue Research Foundation Azaindenoisoquinoline topoisomerase I inhibitors
SI2902029T1 (sl) 2012-09-25 2018-11-30 Chugai Seiyaku Kabushiki Kaisha Inhibitor ret
WO2014063189A1 (en) * 2012-10-23 2014-05-01 Adelaide Research & Innovation Pty Ltd Methods and products for preventing and/or treating a stress induced cardiomyopathy
EP3010055B1 (en) * 2013-06-11 2021-10-20 Idemitsu Kosan Co., Ltd Material for organic electroluminescent elements, organic electroluminescent element using same, and electronic device
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
WO2015163447A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物の新規結晶
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
CA2973857C (en) 2015-01-16 2023-11-07 Chugai Seiyaku Kabushiki Kaisha Combination drug
DE102016214092A1 (de) 2016-07-29 2018-02-01 Alligator Ventilfabrik Gmbh Befestigungsvorrichtung zum Befestigen eines Messsensors, insbesondere Reifendrucksensors, und Verfahren zum Montieren eines Messsensors
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
EP4316598B1 (en) 2018-06-29 2025-06-18 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising a poorly soluble basic agent
BR112021001145A2 (pt) 2018-09-04 2021-04-20 Chugai Seiyaku Kabushiki Kaisha método para a produção de composto tetracíclico
EP3870572A1 (en) * 2018-10-23 2021-09-01 Myelopro Diagnostics and Research GmbH Compounds targeting mutant calreticulin
CN118146221B (zh) * 2024-05-13 2024-10-25 南京市鸿舜医药科技有限公司 一种吡咯并[3,2-b]吡啶类拓扑异构酶抑制剂、制法及其药物组合物和应用
CN118221674B (zh) * 2024-05-27 2025-01-28 南京市鸿舜医药科技有限公司 一种吡咯并[3,2-b]吡啶类Top/HDAC双靶点抑制剂、制法及其药物组合物和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2025932A (en) * 1978-06-13 1980-01-30 Sumitomo Chemical Co Indoloisoquinolines, and Processes for Producing them
JPH07500581A (ja) * 1991-08-29 1995-01-19 ビズクムニイ　ウスタブ　プロ　ファルマシイ　アー　ビオヘミイ，エス．ペー． ６−〔Ｘ−（２−ヒドロキシエチル）アミノアルキル〕−５，１１−ジオキソ−５，６−ジヒドロ−１１Ｈ−インデノ〔１，２−ｃ〕イソキノリン誘導体、それらの製造方法およびそれらの使用
JPH09143166A (ja) * 1995-11-17 1997-06-03 Taiho Yakuhin Kogyo Kk 新規な縮合インダン誘導体及びその塩
US5710162A (en) * 1994-05-20 1998-01-20 Taiho Pharmaceutical Co., Ltd. Condensed-indan derivatives and pharmaceutically acceptable salts thereof
JP2002527396A (ja) * 1998-10-14 2002-08-27 パーデュー リサーチ ファウンデイション 抗腫瘍薬である新規インデノイソイソキノリン類

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
IT1054655B (it) * 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
US4623304A (en) * 1981-12-08 1986-11-18 Sanyo Electric Co., Ltd. Hermetically sealed rotary compressor
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
GB8828806D0 (en) * 1988-12-09 1989-01-18 Beecham Group Plc Novel compounds
US5260316A (en) * 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5597831A (en) * 1991-08-29 1997-01-28 Vufb A.S 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6250301B1 (en) 1997-08-28 2001-06-26 Hortal Harm B.V. Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6346536B1 (en) * 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
WO2000010600A2 (en) * 1998-08-24 2000-03-02 Maxim Pharmaceuticals, Inc. Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
DE59911249D1 (de) 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
OA11749A (en) 1999-01-11 2005-07-19 Agouron Pharma Tricyclic inhibitors of poly(adp-ribose)polymerases.
US6346535B1 (en) * 1999-01-29 2002-02-12 American Cyanamid Company Fungicidal mixtures
AU779215B2 (en) * 1999-07-16 2005-01-13 Maxim Pharmaceuticals, Inc. Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6277990B1 (en) * 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
US6723733B2 (en) * 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
GB0017508D0 (en) 2000-07-17 2000-08-30 Novartis Ag Antimicrobials
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
JP2003267888A (ja) 2002-03-15 2003-09-25 Seishi Yoneda 心停止液
US6992088B2 (en) 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
JPWO2004043959A1 (ja) 2002-11-12 2006-03-09 持田製薬株式会社 新規ｐａｒｐ阻害剤
JP2007501857A (ja) * 2003-02-28 2007-02-01 イノテック ファーマシューティカルズ コーポレーション 四環系ベンズアミド誘導体およびその使用方法
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
KR20060123403A (ko) 2003-12-01 2006-12-01 쿠도스 파마슈티칼스 리미티드 암 치료를 위한 ｄｎａ 손상 수복 억제제
EA200601558A1 (ru) * 2004-02-26 2007-08-31 Инотек Фармасьютикалз Корпорейшн Производные изохинолинов и способы их использования
US20050261288A1 (en) * 2004-02-26 2005-11-24 Prakash Jagtap Tetracyclic lactam derivatives and uses thereof
CA2571001A1 (en) * 2004-06-16 2006-01-26 Inotek Pharmaceuticals Corporation Methods for treating or preventing erectile dysfunction or urinary incontinence
US20060079510A1 (en) * 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
WO2006093677A1 (en) * 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Tetracyclic sulfonamide compounds and methods of use thereof
JP2008531561A (ja) * 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション イソキノリン化合物およびその使用方法
RU2007135362A (ru) * 2005-02-25 2009-03-27 Инотек Фармасьютикалз Корпорейшн (Us) Тетрациклические амино- и карбоксамидосоединения и способ их применения
CN101316592A (zh) * 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2025932A (en) * 1978-06-13 1980-01-30 Sumitomo Chemical Co Indoloisoquinolines, and Processes for Producing them
JPH07500581A (ja) * 1991-08-29 1995-01-19 ビズクムニイ　ウスタブ　プロ　ファルマシイ　アー　ビオヘミイ，エス．ペー． ６−〔Ｘ−（２−ヒドロキシエチル）アミノアルキル〕−５，１１−ジオキソ−５，６−ジヒドロ−１１Ｈ−インデノ〔１，２−ｃ〕イソキノリン誘導体、それらの製造方法およびそれらの使用
US5710162A (en) * 1994-05-20 1998-01-20 Taiho Pharmaceutical Co., Ltd. Condensed-indan derivatives and pharmaceutically acceptable salts thereof
JPH09143166A (ja) * 1995-11-17 1997-06-03 Taiho Yakuhin Kogyo Kk 新規な縮合インダン誘導体及びその塩
JP2002527396A (ja) * 1998-10-14 2002-08-27 パーデュー リサーチ ファウンデイション 抗腫瘍薬である新規インデノイソイソキノリン類

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5006015598, ＷＡＷＺＯＮＥＫ， Ｓ, Ｊ． ＯＲＧ． ＣＨＥＭ, 1996, Ｖ３１, Ｐ１００４−１００６ *
JPN6010045523, Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 1984, Ｖｏｌ．２７，Ｎｏ．４, Ｐ．５４４−５４７ *
JPN6010045525, Ｊ． Ｍｅｄ． Ｃｈｅｍ．, 1985, Ｖｏｌ．２８，Ｎｏ．８, Ｐ．１０３１−１０３６ *
JPN6010045527, Ｉｎｄｉａｎ Ｊｏｕｒｎａｌ ｏｆ Ｃｈｅｍｉｓｔｒｙ, 1985, Ｖｏｌ．２４Ｂ, Ｐ．４４０−４４４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520817A (ja) * 2003-02-28 2006-09-14 イノテック ファーマシューティカルズ コーポレイション イソキノリン誘導体およびその使用方法

Also Published As

Publication number Publication date
CN100398519C (zh) 2008-07-02
CA2517260A1 (en) 2005-02-03
WO2005009398A3 (en) 2005-09-29
PL378331A1 (pl) 2006-03-20
KR20050118169A (ko) 2005-12-15
RU2005130169A (ru) 2006-05-10
US20040229895A1 (en) 2004-11-18
BRPI0407757A (pt) 2006-02-14
AU2004258801A1 (en) 2005-02-03
EP1603567A2 (en) 2005-12-14
US7217709B2 (en) 2007-05-15
US20070249653A1 (en) 2007-10-25
CN1780624A (zh) 2006-05-31
WO2005009398A2 (en) 2005-02-03
EP1603567A4 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
CN100398519C (zh) 四环苯甲酰胺衍生物及其用法
US7652028B2 (en) Indenoisoquinolinone analogs and methods of use thereof
EP2033645A1 (en) Isoquinoline derivatives and methods of use thereof
US20100121049A1 (en) Indenoisoquinolinone analogs and methods of use thereof
US20060287313A1 (en) Isoquinoline compounds and methods of use thereof
US20050261288A1 (en) Tetracyclic lactam derivatives and uses thereof
WO2010077663A2 (en) Substituted tetracyclic 1h-indeno (1,2-b) pyridine-2 (5h)-one analogs thereof and uses thereof
CN101137377A (zh) 四环氨基和甲酰胺基化合物及其用法
WO2006093677A1 (en) Tetracyclic sulfonamide compounds and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110118